NAION and type PDE-5 inhibitors - Erectile Dysfunction

FDA was informed of 43 cases of different vision troubles example, as well as blindness, Among patients who take PDE-5 (5 phosphodiesterase) inhibitors. The majority of such cases of troubles with vision were based on NAION (nonarteritic anterior ischemic optic neuropathy). The vision loss sometimes was even impossible to be prevented.

Because PDE-5 (type 5 phosphodiesterase) inhibitors seem to be the basic element of Cialis, Viagra and Levitra, The US Food and Drug Administration (FDA) produced an article, which warns physicians of possible threat to health.

NAION term denotes a vascular condition which is considered to happen due to blood flow inhibition in the small vessels which feed the optic nerve. A decrease in the blood volume, transported to the nerve causes injury to it. Nerve trauma may be the reason of constant loss of vision in both eyes or only one of them. Patients are commonly over 50 years in age; clinical inspection shows visual field loss, unilateral visual acuity or optic disk edema. No matter how frequently this condition happens, the real reason for it is unknown. A variety of treat aspects were considered, such as hypertension, cup-to-disk ratio, arteriosclerosis, hypercholesterolemia, diabetes mellitus and intraocular post-surgery condition.

Because individuals with impotence are potentially more subjected to microvascular risk aspects traditionally connected with self-existing NAION, ischemic affect by PDE-5 (type 5 phosphodiesterase) inhibitors can occur on optic nerve, but it’s not likely. In individuals with normal health, PDE-5 inhibitors enhanced systaltic ocular blood flow, as a consequence of choroidal circulation.

Although the amount of NAION cases among individuals using different PDE-5 inhibitors is different - 38 events in individuals taking Viagra, 4 in individuals taking Cialis, and 1 case in patient taking Levitra - there exists no proof that one medicine is a matter of higher concern than another. Over 23 million patients has taken Viagra all over the world, over 4,5 million has taken Cialis, and over 1,8 million has used Levitra. Such a variety in the amount of NAION conditions among three PDE-5 inhibitors can be explained by the amount of each medicine taken all over the world but not actual differences in threats presented by the remedies.

We should suggest that individuals who have experienced monocular NAION should know that PDE-5 inhibitors are able to enhance the threat of NAION in the second eye. Simultaneously, individuals who possess potential signs for NAION developing should consult ophthalmologist before taking remedies, which include PDE-5 inhibitors.